SCHEMBL10249140

SCHEMBL10249140

Cc1ccc2c(c1)nc(-c1ccncc1)n2C

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.66
KMT2A Q03164 1/20 0.66
ATM Q13315 1/20 0.54
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49
ACSS2 Q9NR19 1/20 0.48
NLRP3 Q96P20 1/20 0.48
KDM4E B2RXH2 5/20 0.46
HSD17B10 Q99714 5/20 0.46
NPC1 O15118 5/20 0.46
RAB9A P51151 4/20 0.46
ALDH1A1 P00352 4/20 0.46
TP53 P04637 3/20 0.46
MAPT P10636 3/20 0.46
HPGD P15428 3/20 0.46
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
PKM P14618 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10248874 0.87 MEN1 (0.66) MEN1KMT2AATMCA12CA1
SCHEMBL1104834 0.85 NLRP3 (0.65) MEN1KMT2AATMCA12CA1
SCHEMBL17896623 0.84 MEN1 (0.62) MEN1KMT2AATMCA12CA1
SCHEMBL17896717 0.84 MEN1 (0.62) MEN1KMT2AATMCA12CA1
SCHEMBL10030014 0.82 NLRP3 (0.61) MEN1KMT2AATMCA12CA1
SCHEMBL10175820 0.81 MEN1 (0.59) MEN1KMT2AATMCA12CA1
SCHEMBL10249413 0.81 MEN1 (0.63) MEN1KMT2AATMCA12CA1
SCHEMBL167098 0.80 MEN1 (0.57) MEN1KMT2AATMCA12CA1
SCHEMBL10252536 0.80 AGPAT2 (0.46) MEN1KMT2AATMCA12CA1
SCHEMBL10175456 0.80 MEN1 (0.57) MEN1KMT2AATMCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461181-B2 Fused heterocyclic compound and use thereof SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2013-06-11 US disclosed
US-8273764-B2 Fused heterocyclic compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-25 US disclosed
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-07-12 US disclosed
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 MEN1 637/4885KMT2A 1877/4885ATM 4476/4885
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 MEN1 637/4885KMT2A 1877/4885ATM 4476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.